Business Wire22h
SmithRx Introduces Stelara Biosimilars to Its Autoimmune Program, Helping Clients Save a Projected $14.5M in Prescription Drug Costs
SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...
gastroenterologyadvisor23h
Ozanimod Shows Long-Term Efficacy, Safety in Biologic-Exposed Patients With UC
Ozanimod showed a rapid onset of action and efficacy as extended induction therapy in patients with ulcerative colitis nonresponsive to biologics.
manilatimes23h
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis
Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...